Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 13;10(4):e0120519.
doi: 10.1371/journal.pone.0120519. eCollection 2015.

The method quality of cross-over studies involved in Cochrane Systematic Reviews

Affiliations

The method quality of cross-over studies involved in Cochrane Systematic Reviews

Hong Ding et al. PLoS One. .

Abstract

Background: It is possible that cross-over studies included in current systematic reviews are being inadequately assessed, because the current risk of bias tools do not consider possible biases specific to cross-over design. We performed this study to evaluate whether this was being done in cross-over studies included in Cochrane Systematic Reviews (CSRs).

Methods: We searched the Cochrane Library (up to 2013 issue 5) for CSRs that included at least one cross-over trial. Two authors independently undertook the study selection and data extraction. A random sample of the CSRs was selected and we evaluated whether the cross-over trials in these CSRs were assessed according to criteria suggested by the Cochrane handbook. In addition we reassessed the risk of bias of these cross-over trials by a checklist developed form the Cochrane handbook.

Results: We identified 688 CSRs that included one or more cross-over studies. We chose a random sample of 60 CSRs and these included 139 cross-over studies. None of these CSRs undertook a risk of bias assessment specific for cross-over studies. In fact items specific for cross-over studies were seldom considered anywhere in quality assessment of these CSRs. When we reassessed the risk of bias, including the 3 items specific to cross-over trials, of these 139 studies, a low risk of bias was judged for appropriate cross-over design in 110(79%), carry-over effects in 48(34%) and for reporting data in all stages of the trial in 114(82%).Assessment of biases in cross-over trials could affect the GRADE assessment of a review's findings.

Conclusion: The current Cochrane risk of bias tool is not adequate to assess cross-over studies. Items specific to cross-over trials leading to potential risk of bias are generally neglected in CSRs. A proposed check list for the evaluation of cross-over trials is provided.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart for selection of studies.
Fig 2
Fig 2. Summary of the quality assessment of the 139 cross-over trials
1. Appropriate cross-over design; 2. Randomized order of receiving treatment; 3. Carry-over effects; 4. Unbiased data; 5. Allocation concealment; 6. Blinding; 7. Incomplete outcome data; 8. Selective outcome reporting; 9. Other bias

References

    1. Senn SJ. Cross-over trials in clinical research Chichester: John Wiley; 2002; 1.
    1. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991; 133(2): 144–153. - PubMed
    1. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions, version 5.0.2. Available: www.cochrane-handbook.org. 2008; Accessed 29 May 2010.
    1. Cleophas TJ, De Vogel EM. Crossover studies are a better format for comparing equivalent treatments than parallel-group studies. Pharm World Sci. 1998; 20(3): 113–117. - PubMed
    1. Brown BW Jr. The crossover experiment for clinical trials. Biometrics. 1980; 36: 69–79. - PubMed

LinkOut - more resources